Sulforafan alfadex

Drug Profile

Sulforafan alfadex

Alternative Names: SFX-01; Stabilised sulforaphane; Sulforadex; Sulforafan-alpha-cyclodextrin; Sulforaphane-alpha-cyclodextrin; Sulphoraphane-alfadex

Latest Information Update: 24 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evgen Pharma; Lalilab; PharmAgra Labs
  • Developer Evgen Pharma
  • Class Antineoplastics; Chemopreventatives; Phytotherapies
  • Mechanism of Action Androgen receptor antagonists; Hedgehog protein modulators; Histone deacetylase inhibitors; NF E2 related factor 2 stimulants; Signal transduction pathway modulators; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Subarachnoid haemorrhage
  • Preclinical Cardiovascular disorders; Chronic obstructive pulmonary disease; Leukaemia; Multiple sclerosis

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Breast cancer (Second-line therapy or greater, Combination therapy, Metastatic disease, Late-stage disease) in Belgium (PO) (NCT02970682)
  • 14 Sep 2016 Preclinical trials in Multiple sclerosis in United Kingdom (PO)
  • 14 Sep 2016 Pharmacodynamics data from a preclinical study in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top